Cost of Illness of Chronic Hepatitis B Infection in Vietnam

Value in Health Regional Issues

Volumn 1, Issue 1, 2012, Pages 23-28

  Tu, Hong Anh T ^a,b   Woerdenbag, Herman J ^a   Riewpaiboon, Arthorn ^c   Kane, Sumit ^d   Le, Diep M ^e   Postma, Maarten J ^a   Li, Shu Chuen ^f  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b HANOI UNIVERSITY OF PHARMACY   (Viet Nam)

^c MAHIDOL UNIVERSITY   (Thailand)

^d ROYAL TROPICAL INSTITUTE   (Netherlands)

^e BACH MAI HOSPITAL   (Viet Nam)

^f UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Chronic hepatitis B; Cost of illness; Direct medical cost; Indirect,cost

Indexed keywords

LAMIVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; GROSS NATIONAL PRODUCT; HEALTH CARE UTILIZATION; HEPATITIS B; HUMAN; LENGTH OF STAY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REIMBURSEMENT; RESOURCE ALLOCATION; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; VIET NAM;

EID: 84868276154     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2012.03.008     Document Type: Article

References (30)

1. Position paper on hepatitis B World Health Organization, [Accessed January 18, 2010]. http://www.who.int/vaccines/en/hepatitisb.shtm/#strategies.
2. Beasley R.P., Hwang L.Y., Lin C.C., Chien C.S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 1981, 2:1129-1133.
3. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
4. Beasley R.P. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988, 61:1942-1956.
5. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2001, 34:1225-1241.
6. Holliday S.M., Faulds D. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection. Pharmacoeconomics 1994, 5:141-171.
7. Nakata S., Song P., Duc D.D., et al. Hepatitis C and B virus infections in populations at low or high risk in Ho Chi Minh and Hanoi, Vietnam. J Gastroenterol Hepatol 1994, 9:416-419.
8. Tran V.B., Buu M., Nguyen M., Morris G.E. Hepatitis B in Ho Chi Minh City, Viet Nam. Trans R Soc Trop Med Hyg 1993, 87:262.
9. Katelaris P.H., Robertson G., Bradbury R., et al. Seroprevalence of hepatitis viruses in children in rural Viet Nam. Trans R Soc Trop Med Hyg 1995, 89:487.
10. Chen D.S., Hsu N.H., Sung J.L., et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987, 257:2597-2603.
11. Background note: Vietnam US Department of State, [Accessed September 24, 2009]. http://www.state.gov/r/pa/ei/bgn/4130.htm.
12. Tan S.S., Rutten F.F., van Ineveld B.M., et al. Comparing methodologies for the cost estimation of hospital services. Eur J Health Econ 2009, 10:39-45.
13. Bank for Foreign Trade in Vietnam, [Accessed August 28, 2009]. http://www.vietcombank.com.vn.
14. Drummond M.F., O'Brien B.J., Sculpher M.J. Methods for the Economic Evaluation of Health Care Programmes 2003, Oxford University Press, Oxford. 3rd ed.
15. Vietnam Ministry of Labour, Invalids and Social Affairs [Accessed September 21, 2009]. http://www.molisa.org.vn.
16. Nguyen V.T., Law M.G., Dore G.J. An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025. Liver Int 2008, 28:525-531.
17. International database (IDB) US Census Bureau, [Accessed September 18, 2009]. http://www.census.gov/ipc/www/idb/index.html.
18. Ngoan l.T. Cancer mortality in a Hanoi population, Viet Nam, 1996-2005. Asian Pac J Cancer Prev 2006, 7:127-130.
19. Ngoan l.T., Long T.T., Luan N.T., Hang L.T. Population-based cancer survival in sites in Viet Nam. Asian Pac J Cancer Prev 2007, 8:539-542.
20. Ngoan l.T., Lua N.T., Hang L.T. Cancer mortality pattern in Viet Nam. Asian Pac J Cancer Prev 2007, 8:535-538.
21. Hipgrave D.B., Nguyen T.V., Vu M.H., et al. Hepatitis B infection in rural Vietnam and the implications for a national program of infant immunization. Am J Trop Med Hyg 2003, 69:288-294.
22. Lam C.M., Chan A.O., Ho P., et al. Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients-implications for screening. Aliment Pharmacol Ther 2004, 19:771-777.
23. Pawarode A., Tangkijvanich P., Voravud N. Outcomes of primary hepatocellular carcinoma treatment: an 8-year experience with 368 patients in Thailand. J Gastroenterol Hepatol 2000, 15:860-864.
24. Yeung Y.P., Lo C.M., Liu C.L., et al. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005, 100:1995-2004.
25. Lieberman S.S., Wagstaff A. Health Financing and Delivery in Vietnam: Looking Forward 2009, The World Bank, Washington, DC.
26. National health account series 2008, World Health Organization.
27. Hsieh C.R., Kuo C.W. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol 2004, 38(Suppl. 3):S148-S152.
28. Li S.C., Ong S.C., Lim S.G., et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol 2004, 38(Suppl. 3):S136-S143.
29. Yang B.M., Kim C.H., Kim J.Y. Cost of chronic hepatitis B infection in South Korea. J Clin Gastroenterol 2004, 38(Suppl. 3):S153-S157.
30. Nguyen A.T., Knight R., Mant A., et al. Medicine prices, availability, and affordability in Vietnam. Southern Med Rev 2009, 2:2-9.